¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå : ¼ºñ½º À¯Çüº°, Ä¡·á ¿µ¿ªº°, ¿¬·ÉÃþº°, Á¦°ø Çüź°, ¼ºº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Patient Support Programs (PSP) Market, By Service Type, By Therapeutic Area, By Age Group, By Delivery Mode, By Gender, By End User, By Geography
»óǰÄÚµå
:
1747282
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀåÀº 2025³â¿¡ 227¾ï ´Þ·¯, 2032³â¿¡´Â 689¾ï 5,000¸¸ ´Þ·¯¿¡ À̸£°í, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 17.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º¸°í¼ ¹üÀ§
º¸°í¼ »ó¼¼
±âÁØ ¿¬µµ
2024
2025³â ½ÃÀå ±Ô¸ð
227¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ
2020-2024³â
¿¹Ãø ±â°£
2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR
17.20%
2032³â °¡Ä¡ ¿¹Ãø
689¾ï 5,000¸¸ ´Þ·¯
ȯÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP)Àº ÇコÄÉ¾î ¾÷°è¿¡¼ ȯÀÚ¿Í Ã³¹æµÈ Ä¡·á »çÀÌÀÇ °£±ØÀ» ¸Þ¿ì´Â Áß¿äÇÑ ¿ä¼Ò·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. PSP´Â ȯÀÚ°¡ º¹ÀâÇÑ ÀÇ·á ½Ã½ºÅÛÀ» ÀÌ¿ëÇϰí, ÀǾàǰ¿¡ Á¢±ÙÇϰí, Ä¡·á °èȹÀ» ÁؼöÇÒ ¼ö ÀÖµµ·Ï Á¾ÇÕÀûÀÎ Áö¿øÀ» Á¦°øÇϵµ·Ï ¼³°èµÇ¾úÀ¸¸ç, PSP¿¡´Â ÀçÁ¤Àû Áö¿ø, ±³À°Àû ÀÚ¿ø, Á¤½ÅÀû Áö¿ø, Ä¡·á Á¶Á¤ µî ´Ù¾çÇÑ ¼ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. Æ÷ÇÔÇÕ´Ï´Ù. PSP´Â ȯÀÚ°¡ Á÷¸éÇÑ °íÀ¯ÇÑ ¿ä±¸¿Í °úÁ¦¸¦ ÇØ°áÇÔÀ¸·Î½á ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí, »îÀÇ ÁúÀ» Çâ»ó½Ã۸ç, ¸¸¼ºÀûÀÌ°í »ý¸íÀ» À§ÇùÇÏ´Â Áõ»ó¿¡ ´ëÇÑ ºÎ´ãÀ» °æ°¨½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÇコÄɾî ȯ°æÀÌ °è¼Ó º¯ÈÇÔ¿¡ µû¶ó ȯÀÚ Áß½ÉÀÇ Á¢±Ù ¹æ½Ä°ú °³º°ÈµÈ Áö¿ø¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÏ¸é¼ Àü ¼¼°è ȯÀÚ Áö¿ø ÇÁ·Î±×·¥ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ:.
¼¼°è ȯÀÚ Áö¿ø ÇÁ·Î±×·¥ ½ÃÀåÀÇ ¼ºÀåÀº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÇ·áºñ Áõ°¡, ȯÀÚ Áß½É Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ¾Ï°ú °°Àº ¸¸¼º ÁúȯÀÇ ºÎ´ãÀº Àü ¼¼°èÀûÀ¸·Î ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖÀ¸¸ç, ȯÀÚÀÇ »óŸ¦ È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇÑ Á¾ÇÕÀûÀÎ Áö¿ø ¼ºñ½º°¡ ÇÊ¿äÇÕ´Ï´Ù. PSP´Â Áö¿ø ÇÁ·Î±×·¥, º»Àκδã±Ý Áö¿ø ¹× ±âŸ ÀçÁ¤Àû Áö¿øÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ °æÁ¦Àû À庮À» ³·Ãß´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ Áß½É Ä¡·á ¸ðµ¨·ÎÀÇ ÀüȯÀº °³º°ÈµÈ Áö¿ø°ú Âü¿©ÀÇ Á߿伺À» °Á¶Çϸç, ȯÀÚ °³°³ÀÎÀÇ Çʿ信 ¸Â°Ô ¼ºñ½º¸¦ Á¶Á¤ÇÒ ¼ö ÀÖ´Â PSP¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
±×·¯³ª PSP µµÀÔ ¹× °ü¸®ÀÇ º¹À⼺, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹®Á¦, ±ÔÁ¦ ¹®Á¦ µî ½ÃÀå¿¡´Â ÀÏÁ¤ÇÑ Á¦¾à ¿äÀÎÀÌ Á¸ÀçÇÕ´Ï´Ù. ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü, ÁöºÒÀÚ, Á¦¾à»ç µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ°£ÀÇ ¿øÈ°ÇÑ Çù·ÂÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ ¿î¿µÀÌ ¾î·Á¿ï ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ µ¥ÀÌÅ͸¦ º¸È£Çϰí ÁøÈÇÏ´Â ÀÇ·á ±ÔÁ¦¸¦ ÁؼöÇϱâ À§Çؼ´Â °ß°íÇÑ º¸¾È Á¶Ä¡¿Í Áö¼ÓÀûÀÎ ÀûÀÀÀÌ ÇÊ¿äÇÕ´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ȯÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ȯÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ȯÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¼ºÀå ¾ïÁ¦¿äÀÎ
±âȸ
¿µÇ⠺м®
ÁÖ¿ä ¹ßÀü
±ÔÁ¦ ½Ã³ª¸®¿À
Á¦Ç° ¹ß¸Å/½ÂÀÎ
PEST ºÐ¼®
PORTER ºÐ¼®
ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À
¾÷°è µ¿Çâ
Á¦4Àå ¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå, ¼ºñ½º À¯Çüº°, 2020³â-2032³â
º¹¾à Áؼö Áö¿ø
ȯÀÚ ±³À° ¹× Ä«¿î¼¿¸µ
Áúȯ ƯÀÌÀû Äɾî ÄÚµð³×À̼Ç
ÀçÁ¤ ¿øÁ¶ ¹× ȯºÒ
±âŸ
Á¦5Àå ¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå, Ä¡·á ¿µ¿ªº°, 2020³â-2032³â
Á¾¾çÇÐ
½ÉÀ庴ÇÐ
½Å°æÇÐ
¸é¿ªÇÐ
·ù¸ÓƼÁòÇÐ
±âŸ(´ç´¢º´ ¹× °¨¿°Áõ)
Á¦6Àå ¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå, ¿¬·É ±×·ìº°, 2020³â-2032³â
Á¦7Àå ¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå, Á¦°ø Çüź°, 2020³â-2032³â
´ë¸é ¼ºñ½º
µðÁöÅÐ ¼Ö·ç¼Ç
ÇÏÀ̺긮µå ¸ðµ¨
Á¦8Àå ¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå, ¼ºº°, 2020³â-2032³â
Á¦9Àå ¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â
Á¦¾àȸ»ç
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
ÀÇ·á±â±â ±â¾÷
¿ä¾ç½Ã¼³
ÀÇ·á Á¦°øÀÚ
±âŸ(¿¬±¸¼¾ÅÍ µî)
Á¦10Àå ¼¼°èÀÇ È¯ÀÚ Áö¿ø ÇÁ·Î±×·¥(PSP) ½ÃÀå, Áö¿ªº°, 2020³â-2032³â
ºÏ¹Ì
¶óƾ¾Æ¸Þ¸®Ä«
ºê¶óÁú
¾Æ¸£ÇîÆ¼³ª
¸ß½ÃÄÚ
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
À¯·´
µ¶ÀÏ
¿µ±¹
½ºÆäÀÎ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
·¯½Ã¾Æ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
Áß±¹
Àεµ
ÀϺ»
È£ÁÖ
Çѱ¹
ASEAN
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
秵GCC ±¹°¡
À̽º¶ó¿¤
±âŸ Áßµ¿
¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«
ºÏ¾ÆÇÁ¸®Ä«
Áß¾Ó¾ÆÇÁ¸®Ä«
Á¦11Àå °æÀï ±¸µµ
Roche
Novartis
Pfizer
Merck & Co.
Johnson & Johnson
Sanofi
AstraZeneca
GSK(GlaxoSmithKline)
AbbVie
Amgen
Bayer
Eli Lilly and Company
Bristol-Myers Squibb
Takeda Pharmaceutical Company
Biogen
Á¦12Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×
±âȸ
¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
Coherent Opportunity Map
Á¦13Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
Âü°í ¹®Çå
Á¶»ç ¹æ¹ý
ÃâÆÇ»ç¿¡ ´ëÇØ
LSH
¿µ¹® ¸ñÂ÷
The Global Patient Support Programs (PSP) Market is estimated to be valued at USD 22.70 Bn in 2025 and is expected to reach USD 68.95 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.2% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 22.70 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
17.20%
2032 Value Projection:
USD 68.95 Bn
Patient Support Programs (PSPs) have emerged as a crucial component in the healthcare industry, bridging the gap between patients and their prescribed treatments. These programs are designed to provide comprehensive assistance to patients, enabling them to navigate the complexities of healthcare systems, access medications, and adhere to their treatment plans. PSPs encompass a wide range of services, including financial assistance, educational resources, emotional support, and care coordination. By addressing the unique needs and challenges faced by patients, PSPs aim to improve patient outcomes, enhance the quality of life, and reduce the burden of chronic and life-altering conditions. As the healthcare landscape continues to evolve, the demand for patient-centric approaches and personalized support has grown significantly, driving the expansion of the global patient support programs market.
Market Dynamic:
The global patient support programs market growth is driven by several key factors, including the rising prevalence of chronic diseases, increasing healthcare costs, and the growing need for patient-centric care. The burden of chronic conditions, such as diabetes, cardiovascular disorders, and cancer, has been steadily increasing worldwide, necessitating comprehensive support services to help patients manage their conditions effectively. Moreover, the escalating costs of healthcare, particularly in terms of prescription medications and treatments, have created a significant financial strain on patients and their families. PSPs play a crucial role in mitigating these financial barriers by providing assistance programs, copay support, and other forms of financial aid. Furthermore, the shift towards patient-centric care models has highlighted the importance of personalized support and engagement, driving the demand for PSPs that can tailor their services to individual patient needs.
However, the market also faces certain restraints, such as the complexity of implementing and managing PSPs, data privacy concerns, and regulatory challenges. The need for seamless coordination among various stakeholders, including healthcare providers, payers, and pharmaceutical companies, can pose operational difficulties. Additionally, ensuring the protection of patient data and compliance with evolving healthcare regulations requires robust security measures and continuous adaptation.
Key features of the study:
This report provides in-depth analysis of the global Patient Support Programs (PSP) market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global patient support programs (PSP) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Roche, Novartis, Pfizer, Merck & Co., Johnson & Johnson, Sanofi, AstraZeneca, GSK (GlaxoSmithKline), AbbVie, Amgen, Bayer, Eli Lilly and Company, Bristol-Myers Squibb, Takeda Pharmaceutical Company, and Biogen.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global patient support programs (PSP) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global patient support programs (PSP) market
Market Segmentation
Service Type Insights (Revenue, USD Bn, 2020 - 2032)
Medication Adherence Support
Patient Education & Counseling
Disease-Specific Care Coordination
Remote Patient Monitoring
Financial Assistance & Reimbursement
Others
Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
Oncology
Cardiology
Neurology
Immunology
Rheumatology
Others (Diabetes and Infectious Diseases)
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
Pediatric
Adult
Geriatric
Delivery Mode Insights (Revenue, USD Bn, 2020 - 2032)
In-person Services
Digital Solutions
Hybrid Models
Gender Insights (Revenue, USD Bn, 2020 - 2032)
End User Insights (Revenue, USD Bn, 2020 - 2032)
Pharmaceutical Companies
Biotechnology Companies
Medical Device Companies
Assisted Living facilities
Healthcare Providers
Others (Research Centers, etc.)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Key Players Insights
Roche
Novartis
Pfizer
Merck & Co.
Johnson & Johnson
Sanofi
AstraZeneca
GSK (GlaxoSmithKline)
AbbVie
Amgen
Bayer
Eli Lilly and Company
Bristol-Myers Squibb
Takeda Pharmaceutical Company
Biogen
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Global Patient Support Programs (PSP) Market, By Service Type
Global Patient Support Programs (PSP) Market, By Therapeutic Area
Global Patient Support Programs (PSP) Market, By Age Group
Global Patient Support Programs (PSP) Market, By Delivery Mode
Global Patient Support Programs (PSP) Market, By Gender
Global Patient Support Programs (PSP) Market, By End User
Global Patient Support Programs (PSP) Market, By Region
3. Market Dynamics, Regulations, And Trends Analysis
Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends
4. Global Patient Support Programs (PSP) Market, By Service Type, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Medication Adherence Support
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Patient Education & Counseling
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Disease-Specific Care Coordination
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Financial Assistance & Reimbursement
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Patient Support Programs (PSP) Market, By Therapeutic Area, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Oncology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Neurology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Immunology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rheumatology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Diabetes and Infectious Diseases)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Patient Support Programs (PSP) Market, By Age Group, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Pediatric
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Adult
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Patient Support Programs (PSP) Market, By Delivery Mode, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
In-person Services
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Digital Solutions
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hybrid Models
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Patient Support Programs (PSP) Market, By Gender, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Male
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Patient Support Programs (PSP) Market, By End User, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Pharmaceutical Companies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biotechnology Companies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Medical Device Companies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Assisted Living facilities
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Healthcare Providers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Research Centers, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Patient Support Programs (PSP) Market, By Region, 2020 - 2032, Value (USD Bn)
Introduction
Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Service Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Latin America
Introduction
Market Size and Forecast, By Service Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Service Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Service Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Service Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Service Type, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Delivery Mode, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
South Africa
North Africa
Central Africa
11. Competitive Landscape
Roche
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GSK (GlaxoSmithKline)
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Amgen
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bayer
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Takeda Pharmaceutical Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Biogen
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
12. Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
13. References and Research Methodology
References
Research Methodology
About us
°ü·ÃÀÚ·á